Highlights ViroGates A/S

Equities

VIRO

DK0061030574

Market Closed - Nasdaq Copenhagen Other stock markets 06:10:30 14/05/2024 pm IST			5-day change	1st Jan Change
6.76 ^DKK	-1.46%		-1.17%	+12.29%

02/05	ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
15/04	Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05	CI
Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration	15/04	CI
ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
ViroGates A/S Provides Earnings Guidance for the Year 2024	21/12	CI
ViroGates A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
ViroGates A/S Announces Positive Results from a Randomized Controlled Clinical Trial on Supar-Guided Antibody Treatment in Sepsis	22/23/22	CI
ViroGates A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17/23/17	CI
Virogates Provides Earnings Guidance for 2023	17/23/17	CI
ViroGates A/S Announces an Agreement with Sobi for the Development of Suparnostic®	02/23/02	CI
ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	04/23/04	CI
ViroGates A/S Announces the Commercial Launch of suPARnostic POC+ Product	24/23/24	CI
ViroGates A/S Announces CE-IVD approval for suPARnostic® TurbiLatex on the Roche Diagnostics cobas® Pure and Pro instrument platforms	06/23/06	CI
ViroGates A/S Revises Earnings Guidance for Full-Year 2022 and 2023	16/22/16	CI
ViroGates A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10	CI
ViroGates A/S Announces the Publication of A New Study That Shows SsuPAR upar Causes Cardiovascular Disease	05/22/05	CI
ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Beckman Coulter AU5800 platform	23/22/23	CI
ViroGates A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	18/22/18	CI
ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023	22/22/22	CI
ViroGates Announces the CE-Ivd Accreditation of Its Finger-Prick Blood-Testing Product, Suparnostic® Poc+	25/22/25	CI
ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2022	04/22/04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ViroGates A/S

Equities

VIRO

DK0061030574

Highlights

Filters